Dr Reddy's Looking For “Bigger Than Usual” Deals But Not In A Rush
Strikes deal with Hengrui for pyrotinib
Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.
